Healthtech startup ErlySign has raised ₹16 crore ($1.8 million) in its pre-Series A funding round, led by investor Ashish Kacholia.
The funds will be used to complete clinical trials, obtain CDSCO approvals, and launch its oral cancer detection kit. It will also support R&D, team expansion, and new patent filings.
About ErlySign
Founded in 2019 by Shubhendra Singh Thakur and Deovrat Begde, ErlySign focuses on early oral cancer detection.
Its flagship biomarker-based test kit identifies precancerous conditions within 15 minutes using a non-invasive saliva sample.
“Our initial studies have shown 100% specificity and 98.04% sensitivity. Currently in the final stages of clinical trials across multiple HCG sites, this product could eliminate unnecessary biopsies and invasive procedures,” said Shubhendra Singh Thakur, CEO of ErlySign.
Also Read:
KisaanSay Secures $2 Million in Pre-Seed Funding Led by Jungle Ventures
Looking ahead, ErlySign plans to utilize CRISPR miRNA-based testing to detect multiple cancers from a single saliva sample in just 15–20 minutes, aiming to make early detection more accurate and accessible.
The company has achieved significant milestones, including securing Indian and U.S. patents in 2022 and 2023, further solidifying its position as an innovator in cancer diagnostics.
